Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDOSCLAD: MSCs for Chronic Lung Allograft Dysfunction
NCT06514378Phase 1Recruiting
- Sponsor
- Instituto de Investigación Sanitaria Puerta de Hierro
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cells in chronic lung allograft dysfunction (CLAD) (2 arms), sponsored by Instituto de Investigación Sanitaria Puerta de Hierro. Primary endpoints: Early onset adverse events at 24 hours and Adverse events at 1 year. Started Sep 2023; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on NCT06514378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514378.